Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

CLDXCelldex Therapeutics, Inc.

Nasdaq · CIK 0000744218
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2835 In Vitro & In Vivo Diagnostic Substances
FY end1231
XBRL facts303

Identity from submissions API

NameCelldex Therapeutics, Inc.
CIK0000744218
TickersCLDX
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2835 In Vitro & In Vivo Diagnostic Substances
EIN133191702
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone908-200-7500
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • AVANT IMMUNOTHERAPEUTICS INC (1998-09-01T04:00:00.000Z → 2008-09-29T04:00:00.000Z)
  • T CELL SCIENCES INC (1995-11-14T05:00:00.000Z → 1998-08-21T04:00:00.000Z)
Business address
53 FRONTAGE ROAD
SUITE 220
HAMPTON
NJ
08827
NJ
Mailing address
53 FRONTAGE ROAD
SUITE 220
HAMPTON
NJ
08827
NJ

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

1299 filing rows loaded from submissions recent; extra archives: CIK0000744218-submissions-001.json (299 filings, 1995-04-06 to 2007-11-05).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902219-26-000376 005-37761 261557886 34 17593
2026-11-05 S-3ASR S-3ASR 0001104659-26-123391 333-299858 261527999 33 592821 1 1
2026-11-05 10-Q 10-Q 0001104659-26-123322 000-15006 261527246 34 7135027 1 1
2026-11-05 8-K FORM 8-K 2.02,9.01 0001171843-26-007174 000-15006 261527011 34 293727 1 1
2026-10-07 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002325 005-37761 261446094 34 11973
2026-09-22 8-K FORM 8-K 8.01,9.01 0001104659-26-109465 000-15006 261395233 34 245657 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001907884-26-000013 005-37761 261278482 34 9614
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000080255-26-000537 005-37761 261277428 34 7814
2026-08-06 10-Q 10-Q 0001104659-26-091984 000-15006 261248902 34 6679134 1 1
2026-08-06 8-K FORM 8-K 2.02,9.01 0001171843-26-005316 000-15006 261248702 34 292293 1 1
2026-07-15 8-K FORM 8-K 5.02,9.01 0001104659-26-083880 000-15006 261177464 34 188085 1 1
2026-06-29 4 xslF345X06/form4-06292026_080655.xml 0001960596-26-000004 6034
2026-06-29 4 xslF345X06/form4-06292026_080612.xml 0001838114-26-000002 6048
2026-06-29 4 xslF345X06/form4-06292026_080627.xml 0001648010-26-000002 6039
2026-06-29 4 xslF345X06/form4-06292026_080629.xml 0001718112-26-000002 6054
2026-06-29 4 xslF345X06/form4-06292026_080644.xml 0001709024-26-000004 6048
2026-06-29 4 xslF345X06/form4-06292026_080653.xml 0001709113-26-000002 6049
2026-06-29 4 xslF345X06/form4-06292026_080604.xml 0001681854-26-000002 6043
2026-06-29 4 xslF345X06/form4-06292026_080606.xml 0001214504-26-000002 6033
2026-06-29 4 xslF345X06/form4-06292026_080620.xml 0001429931-26-000002 6029
2026-06-29 4 xslF345X06/form4-06292026_080621.xml 0001429933-26-000002 6044
2026-06-29 4 xslF345X06/form4-06292026_080636.xml 0001820278-26-000008 5777
2026-06-29 4 xslF345X06/form4-06292026_080641.xml 0001707797-26-000012 5825
2026-06-29 4 xslF345X06/form4-06292026_080652.xml 0001586785-26-000008 5847
2026-06-29 4 xslF345X06/form4-06292026_080658.xml 0001529371-26-000005 5828
2026-06-29 4 xslF345X06/form4-06292026_080611.xml 0001518575-26-000002 5838
2026-06-29 4 xslF345X06/form4-06292026_080625.xml 0001198578-26-000002 5832
2026-06-29 4 xslF345X06/form4-06292026_080622.xml 0001218815-26-000002 5838
2026-06-29 4 xslF345X06/form4-06292026_080629.xml 0001131148-26-000002 5839
2026-06-26 S-8 FORM S-8 0001104659-26-078233 333-297059 261128923 33 214339 1 1
2026-06-26 8-K FORM 8-K 5.02,5.07,9.01 0001104659-26-078023 000-15006 261124002 34 226254 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001907884-26-000009 005-37761 26986637 34 9621
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062330 005-37761 26985868 34 10085
2026-05-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000217 005-37761 26966445 34 8384
2026-05-07 10-Q 10-Q 0001104659-26-057113 000-15006 26953184 34 5794246 1 1
2026-05-07 8-K FORM 8-K 2.02,9.01 0001171843-26-003153 000-15006 26952941 34 276320 1 1
2026-05-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-001146 005-37761 26946620 34 11378
2026-04-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-000279 005-37761 26918298 34 7647
2026-04-29 ARS ARS 0001104659-26-050885 000-15006 26910622 34 2731009
2026-04-29 DEF 14A FORM DEF 14A 0001104659-26-050884 000-15006 26910609 34 5772763 1 1
2026-04-02 424B5 424B5 0001104659-26-039255 333-275300 26835319 33 592885 1 1
2026-04-02 8-K FORM 8-K 1.01,8.01,9.01 0001104659-26-038882 000-15006 26830707 34 592092 1 1
2026-04-01 424B5 424B5 0001104659-26-038501 333-275300 26828183 33 436058
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-000983 005-37761 26799452 34 7412
2026-03-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001544 005-37761 26740953 34 12382
2026-02-25 10-K 10-K 0001104659-26-019652 000-15006 26678501 34 10877826 1 1
2026-02-25 8-K FORM 8-K 2.02,9.01 0001171843-26-001098 000-15006 26678336 34 296763 1 1
2026-02-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-26-000058 005-37761 26614290 34 17450
2026-02-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-26-000033 005-37761 26609507 34 8279
2026-01-06 4 xslF345X05/form4-01062026_090142.xml 0001709024-26-000002 7076
2025-12-17 4 xslF345X05/form4-12172025_091230.xml 0001214504-25-000007 11536
2025-12-08 4 xslF345X05/form4-12082025_091231.xml 0001838114-25-000007 4856
2025-12-04 144 xsl144X01/primary_doc.xml 0001950047-25-009745 000-15006 251549389 33 4958
2025-11-17 4 xslF345X05/form4-11172025_091104.xml 0001646423-25-000007 16537
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-112821 005-37761 251488965 34 9448
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001831942-25-000031 005-37761 251488076 34 11704
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000080255-25-000800 005-37761 251483432 34 7908
2025-11-13 144 xsl144X01/primary_doc.xml 0001950047-25-008818 000-15006 251478682 33 4966
2025-11-12 4 xslF345X05/form4-11122025_091122.xml 0001960596-25-000008 5885
2025-11-12 3 xslF345X02/form3-11122025_091156.xml 0001960596-25-000006 8678
2025-11-10 10-Q 10-Q 0001104659-25-109137 000-15006 251466185 34 6958128 1 1
2025-11-10 8-K FORM 8-K 2.02,9.01 0001171843-25-007179 000-15006 251466030 34 301129 1 1
2025-11-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000372 005-37761 251460621 34 17447
2025-08-19 8-K FORM 8-K 8.01,9.01 0001104659-25-080248 000-15006 251231708 34 230380 1 1
2025-08-15 4 xslF345X05/form4-08152025_080825.xml 0001415889-25-022069 6529
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001580642-25-005132 005-37761 251217829 34 11933
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000286 005-37761 251204926 34 17452
2025-08-07 10-Q 10-Q 0001410578-25-001610 000-15006 251193941 34 6519173 1 1
2025-08-07 8-K FORM 8-K 2.02,9.01 0001171843-25-005181 000-15006 251193791 34 280976 1 1
2025-07-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-002963 005-37761 251116439 34 18232
2025-06-09 4 xslF345X05/form4-06092025_080647.xml 0001415889-25-016260 5911
2025-06-09 4 xslF345X05/form4-06092025_080605.xml 0001415889-25-016257 5902
2025-06-09 4 xslF345X05/form4-06092025_080648.xml 0001415889-25-016255 5916
2025-06-09 4 xslF345X05/form4-06092025_080659.xml 0001415889-25-016244 5910
2025-06-09 4 xslF345X05/form4-06092025_080614.xml 0001415889-25-016242 5910
2025-06-09 4 xslF345X05/form4-06092025_080610.xml 0001415889-25-016241 5895
2025-06-09 4 xslF345X05/form4-06092025_080613.xml 0001415889-25-016238 5901
2025-06-09 4 xslF345X05/form4-06092025_080623.xml 0001415889-25-016230 5888
2025-06-09 4 xslF345X05/form4-06092025_080629.xml 0001415889-25-016227 5906
2025-06-09 4 xslF345X05/form4-06092025_080642.xml 0001415889-25-016226 5750
2025-06-09 4 xslF345X05/form4-06092025_080641.xml 0001415889-25-016225 5688
2025-06-09 4 xslF345X05/form4-06092025_080657.xml 0001415889-25-016222 5710
2025-06-09 4 xslF345X05/form4-06092025_080604.xml 0001415889-25-016220 5702
2025-06-09 4 xslF345X05/form4-06092025_080631.xml 0001415889-25-016219 5701
2025-06-09 4 xslF345X05/form4-06092025_080645.xml 0001415889-25-016217 5695
2025-06-09 4 xslF345X05/form4-06092025_080604.xml 0001415889-25-016216 5701
2025-06-09 4 xslF345X05/form4-06092025_080601.xml 0001415889-25-016215 5691
2025-06-06 S-8 FORM S-8 0001104659-25-057296 333-287839 251030450 33 186835 1 1
2025-06-06 3 OWNERSHIP DOCUMENT 0001104659-25-057069 8365
2025-06-06 8-K FORM 8-K 5.02,5.07,9.01 0001104659-25-057066 000-15006 251028926 34 250389 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-003253 005-37761 25950311 34 9539
2025-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000176 005-37761 25933439 34 17430
2025-05-08 10-Q 10-Q 0001410578-25-001111 000-15006 25925986 34 5699720 1 1
2025-05-08 8-K FORM 8-K 2.02,9.01 0001171843-25-002980 000-15006 25925821 34 274591 1 1
2025-04-21 ARS ARS 0001104659-25-036833 000-15006 25853185 34 19805086
2025-04-21 DEF 14A FORM DEF 14A 0001104659-25-036562 000-15006 25851334 34 5933590 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000573 005-37761 25844512 34 11253
2025-04-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001641172-25-003604 005-37761 25828341 34 17620
2025-02-27 10-K 10-K 0001410578-25-000216 000-15006 25678667 34 9188778 1 1
2025-02-27 8-K FORM 8-K 2.02,9.01 0001171843-25-001126 000-15006 25678504 34 291336 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-001723 005-37761 25630916 34 9629
2025-02-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000080255-25-000177 005-37761 25624046 34 7713
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000856 005-37761 25612540 34 11811
2025-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-001193 005-37761 25592180 34 12302
2024-11-20 4 xslF345X05/form4-11202024_091142.xml 0001415889-24-027329 5054
2024-11-14 SC 13G/A p24-3151sc13ga.htm 0000902664-24-006640 005-37761 241465284 34 63770
2024-11-14 SC 13G/A SC 13G/A 0001580642-24-006951 005-37761 241459279 34 56540
2024-11-14 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-24-006486 005-37761 241456852 34 64381
2024-11-13 SC 13G/A polar-cldx093024a1.htm 0001172661-24-004709 005-37761 241456004 34 88114
2024-11-12 SC 13G/A filing.txt 0000315066-24-002724 005-37761 241444515 34 8453
2024-11-12 4 xslF345X05/form4-11122024_011107.xml 0001415889-24-026489 5007
2024-11-08 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000467 005-37761 241438666 34 36391
2024-11-06 10-Q 10-Q 0001410578-24-001766 000-15006 241430907 34 6163566 1 1
2024-11-06 8-K FORM 8-K 2.02,9.01 0001171843-24-006056 000-15006 241430782 34 278222 1 1
2024-08-08 10-Q 10-Q 0001410578-24-001219 000-15006 241188191 34 5828844 1 1
2024-08-08 8-K FORM 8-K 2.02,9.01 0001171843-24-004603 000-15006 241188051 34 300601 1 1
2024-06-18 4 xslF345X05/form4-06182024_080610.xml 0001415889-24-017363 12800
2024-06-18 4 xslF345X05/form4-06182024_080610.xml 0001415889-24-017362 9109
2024-06-17 4 xslF345X05/form4-06172024_080643.xml 0001415889-24-017190 5918
2024-06-17 4 xslF345X05/form4-06172024_080635.xml 0001415889-24-017186 5866
2024-06-17 4 xslF345X05/form4-06172024_080655.xml 0001415889-24-017184 5924
2024-06-17 4 xslF345X05/form4-06172024_080619.xml 0001415889-24-017182 5919
2024-06-17 4 xslF345X05/form4-06172024_080638.xml 0001415889-24-017179 5910
2024-06-17 4 xslF345X05/form4-06172024_080608.xml 0001415889-24-017177 5909
2024-06-17 4 xslF345X05/form4-06172024_080640.xml 0001415889-24-017175 5870
2024-06-17 4 xslF345X05/form4-06172024_080654.xml 0001415889-24-017163 5918
2024-06-17 4 xslF345X05/form4-06172024_080615.xml 0001415889-24-017161 5840
2024-06-17 4 xslF345X05/form4-06172024_080622.xml 0001415889-24-017159 5862
2024-06-17 4 xslF345X05/form4-06172024_080640.xml 0001415889-24-017158 5698
2024-06-17 4 xslF345X05/form4-06172024_080651.xml 0001415889-24-017155 5692
2024-06-17 4 xslF345X05/form4-06172024_080620.xml 0001415889-24-017153 5692
2024-06-17 4 xslF345X05/form4-06172024_080643.xml 0001415889-24-017151 5665
2024-06-17 4 xslF345X05/form4-06172024_080622.xml 0001415889-24-017141 5687
2024-06-17 4 xslF345X05/form4-06172024_080647.xml 0001415889-24-017140 5706
2024-06-17 4 xslF345X05/form4-06172024_080614.xml 0001415889-24-017138 5743
2024-06-17 4 xslF345X05/form4-06172024_080638.xml 0001415889-24-017137 5700
2024-06-14 144 xsl144X01/primary_doc.xml 0001972362-24-000916 000-15006 241046152 33 6364
2024-06-14 144 xsl144X01/primary_doc.xml 0001972362-24-000913 000-15006 241045932 33 6866
2024-06-14 S-8 FORM S-8 0001104659-24-071737 333-280207 241044611 33 92022
2024-06-14 8-K FORM 8-K 5.02,5.07,9.01 0001104659-24-071512 000-15006 241043176 34 231090 1 1
2024-06-13 4 xslF345X05/form4-06132024_080617.xml 0001415889-24-016651 7013
2024-06-11 4 xslF345X05/form4-06112024_080653.xml 0001415889-24-016345 12852
2024-06-11 4 xslF345X05/form4-06112024_080650.xml 0001415889-24-016344 5373
2024-06-07 144 xsl144X01/primary_doc.xml 0001972362-24-000871 000-15006 241030745 33 4453
2024-06-07 144 xsl144X01/primary_doc.xml 0001972362-24-000866 000-15006 241030420 33 5844
2024-06-07 4 xslF345X05/form4-06072024_080609.xml 0001415889-24-015950 7148
2024-06-05 4 xslF345X05/form4-06052024_080636.xml 0001415889-24-015544 12950
2024-06-05 4 xslF345X05/form4-06052024_080641.xml 0001415889-24-015543 18791
2024-06-05 4 xslF345X05/form4-06052024_080652.xml 0001415889-24-015542 8622
2024-06-03 144 xsl144X01/primary_doc.xml 0001972362-24-000831 000-15006 241015275 33 4508
2024-06-03 144 xsl144X01/primary_doc.xml 0001972362-24-000827 000-15006 241014866 33 4511
2024-06-03 4 xslF345X05/form4-06032024_080622.xml 0001415889-24-015148 16830
2024-06-03 4 xslF345X05/form4-06032024_080645.xml 0001415889-24-015147 9262
2024-06-03 4 xslF345X05/form4-06032024_080652.xml 0001415889-24-015138 13074
2024-06-03 4 xslF345X05/form4-06032024_080604.xml 0001415889-24-015137 12870
2024-05-30 144 xsl144X01/primary_doc.xml 0001972362-24-000812 000-15006 241006970 33 4504
2024-05-30 144 xsl144X01/primary_doc.xml 0001972362-24-000811 000-15006 241006963 33 7117
2024-05-30 144 xsl144X01/primary_doc.xml 0001972362-24-000809 000-15006 241006918 33 5040
2024-05-30 144 xsl144X01/primary_doc.xml 0001972362-24-000804 000-15006 241004450 33 5049
2024-05-06 10-Q 10-Q 0001410578-24-000593 000-15006 24917532 34 5227772 1 1
2024-05-06 8-K FORM 8-K 2.02,9.01 0001171843-24-002570 000-15006 24917393 34 268854 1 1
2024-04-25 ARS ARS 0001104659-24-051958 000-15006 24876200 34 2506786
2024-04-25 DEF 14A DEF 14A 0001104659-24-051634 000-15006 24873064 34 3599893 1 1
2024-03-01 8-K FORM 8-K 1.01,8.01,9.01 0001104659-24-029969 000-15006 24709756 34 625595 1 1
2024-03-01 424B5 424B5 0001104659-24-029958 333-275300 24709714 33 459381
2024-02-28 424B5 424B5 0001104659-24-028718 333-275300 24695422 33 418032
2024-02-26 424B5 424B5 0001104659-24-027306 333-275300 24673635 33 390027
2024-02-26 10-K 10-K 0001410578-24-000076 000-15006 24673521 34 8867514 1 1
2024-02-26 8-K FORM 8-K 2.02,9.01 0001171843-24-000966 000-15006 24673512 34 292085 1 1
2024-02-15 4 xslF345X05/form4-02152024_090240.xml 0001415889-24-003891 11513
2024-02-14 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-24-001707 005-37761 24638560 34 66374
2024-02-14 SC 13G KYNAM CAPITAL MANAGEMENT, LP 0001085146-24-001357 005-37761 24635202 34 44356
2024-02-14 SC 13G SC 13G 0001580642-24-000979 005-37761 24634622 34 55399
2024-02-14 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-24-001565 005-37761 24632339 34 63553
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020559 005-37761 24627676 34 13293
2024-02-13 SC 13G polar-cldx123123.htm 0001172661-24-000763 005-37761 24623003 34 88096
2024-02-09 SC 13G/A filing.txt 0000315066-24-001069 005-37761 24611506 34 8456
2024-02-08 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000057 005-37761 24607279 34 38189
2024-01-26 SC 13G/A us15117b2025_012624.txt 0001086364-24-004828 005-37761 24569151 34 13861
2024-01-04 4 xslF345X05/form4-01042024_090138.xml 0001415889-24-000592 7080
2023-11-20 SC 13G CELLDEX THERAPEUTICS, INC. 0000902664-23-005657 005-37761 231422917 34 71028
2023-11-08 8-K FORM 8-K 1.01,8.01,9.01 0001104659-23-115796 000-15006 231389089 34 622392 1 1
2023-11-08 424B5 424B5 0001104659-23-115792 333-275300 231389067 33 527250
2023-11-07 424B5 424B5 0001104659-23-115217 333-275300 231383547 33 488250
2023-11-06 8-K FORM 8-K 8.01 0001104659-23-114520 000-15006 231378497 34 215649 1 1
2023-11-03 S-3ASR S-3ASR 0001104659-23-114270 333-275300 231376228 33 290025
2023-11-02 10-Q 10-Q 0001410578-23-002169 000-15006 231372234 34 5978718 1 1
2023-11-02 8-K FORM 8-K 2.02,9.01 0001171843-23-006668 000-15006 231372054 34 294932 1 1
2023-08-08 10-Q 10-Q 0001410578-23-001588 000-15006 231151232 34 5692634 1 1
2023-08-08 8-K FORM 8-K 2.02,9.01 0001171843-23-005101 000-15006 231151047 34 292838 1 1
2023-06-21 S-8 FORM S-8 0001104659-23-073322 333-272804 231029855 33 70821
2023-06-20 4 xslF345X04/form4-06202023_080658.xml 0001415889-23-010049 5784
2023-06-20 4 xslF345X04/form4-06202023_080633.xml 0001415889-23-010048 5833
2023-06-20 4 xslF345X04/form4-06202023_080630.xml 0001415889-23-010047 5794
2023-06-20 4 xslF345X04/form4-06202023_080654.xml 0001415889-23-010046 5836
2023-06-20 4 xslF345X04/form4-06202023_080605.xml 0001415889-23-010045 5836
2023-06-20 4 xslF345X04/form4-06202023_080633.xml 0001415889-23-010044 5842
2023-06-20 4 xslF345X04/form4-06202023_080649.xml 0001415889-23-010043 5830
2023-06-20 4 xslF345X04/form4-06202023_080654.xml 0001415889-23-010042 5837
2023-06-20 4 xslF345X04/form4-06202023_080658.xml 0001415889-23-010041 5764
2023-06-20 4 xslF345X04/form4-06202023_080657.xml 0001415889-23-010039 5786
2023-06-20 4 xslF345X04/form4-06202023_080621.xml 0001415889-23-010038 5589
2023-06-20 4 xslF345X04/form4-06202023_080641.xml 0001415889-23-010037 5624
2023-06-20 4 xslF345X04/form4-06202023_080604.xml 0001415889-23-010036 5610
2023-06-20 4 xslF345X04/form4-06202023_080610.xml 0001415889-23-010035 5611
2023-06-20 4 xslF345X04/form4-06202023_080626.xml 0001415889-23-010034 5630
2023-06-20 4 xslF345X04/form4-06202023_080641.xml 0001415889-23-010033 5610
2023-06-20 4 xslF345X04/form4-06202023_080655.xml 0001415889-23-010032 5667
2023-06-15 8-K FORM 8-K 5.07,9.01 0001104659-23-071597 000-15006 231017331 34 234938 1 1
2023-05-10 SC 13G/A SEC SCHEDULE 13G 0000902219-23-000024 005-37761 23904514 34 38072
2023-05-04 10-Q FORM 10-Q 0001104659-23-055992 000-15006 23888593 34 4972317 1 1
2023-05-04 8-K FORM 8-K 2.02,9.01 0001171843-23-002887 000-15006 23888456 34 272420 1 1
2023-04-25 ARS ARS 0001104659-23-049609 000-15006 23844853 34 3449355
2023-04-25 DEF 14A DEF 14A 0001104659-23-049299 000-15006 23841804 34 6882382 1 1
2023-03-22 8-K FORM 8-K 8.01 0001104659-23-035198 000-15006 23750851 34 206664 1 1
2023-02-28 10-K FORM 10-K 0001104659-23-026701 000-15006 23685135 34 8466247 1 1
2023-02-28 8-K FORM 8-K 2.02,9.01 0001171843-23-001254 000-15006 23685031 34 308847 1 1
2023-02-21 4 xslF345X03/ownership.xml 0001493152-23-005663 5686
2023-02-21 3 xslF345X02/ownership.xml 0001493152-23-005658 12046
2023-02-21 8-K FORM 8-K 5.02,7.01,9.01 0001104659-23-023768 000-15006 23647986 34 229207 1 1
2023-02-14 SC 13G/A SC 13G/A 0001140361-23-006807 005-37761 23626272 34 327249
2023-02-14 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-23-001725 005-37761 23623860 34 62520
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015586 005-37761 23602705 34 13212
2023-02-09 SC 13G/A filing.txt 0000315066-23-001436 005-37761 23601745 34 8374
2023-02-06 SC 13G SEC SCHEDULE 13G 0000846087-23-000092 005-37761 23590061 34 38151
2023-02-01 SC 13G/A Celldex_Therapeutics_Inc.txt 0000093751-23-000067 005-37761 23575126 34 8668
2023-02-01 SC 13G/A us15117b2025_013123.txt 0001306550-23-005854 005-37761 23573863 34 13604
2022-12-09 4 xslF345X03/form4-12092022_091203.xml 0001415889-22-012301 9049
2022-11-09 10-Q FORM 10-Q 0001104659-22-116466 000-15006 221372563 34 6765086 1 1
2022-11-09 8-K FORM 8-K 2.02,9.01 0001171843-22-007291 000-15006 221372446 34 297783 1 1
2022-08-19 4 xslF345X03/form4-08192022_010836.xml 0001415889-22-008896 14946
2022-08-19 4 xslF345X03/form4-08192022_010835.xml 0001415889-22-008895 12733
2022-08-17 4 xslF345X03/form4-08172022_010842.xml 0001415889-22-008769 13230
2022-08-17 4 xslF345X03/form4-08172022_010827.xml 0001415889-22-008767 9048
2022-08-15 4 xslF345X03/form4-08152022_010833.xml 0001415889-22-008608 22440
2022-08-08 10-Q FORM 10-Q 0001104659-22-087222 000-15006 221144349 34 5816663 1 1
2022-08-08 8-K FORM 8-K 2.02,9.01 0001171843-22-005457 000-15006 221144226 34 307729 1 1
2022-07-18 8-K FORM 8-K 1.01,9.01 0001104659-22-080483 000-15006 221089214 34 270828 1 1
2022-06-23 8-K FORM 8-K 1.01,2.02,9.01 0001104659-22-073889 000-15006 221035432 34 239489 1 1
2022-06-17 4 xslF345X03/form4-06172022_010604.xml 0001415889-22-006733 5801
2022-06-17 4 xslF345X03/form4-06172022_010617.xml 0001415889-22-006732 5804
2022-06-17 4 xslF345X03/form4-06172022_010609.xml 0001415889-22-006731 5805
2022-06-17 4 xslF345X03/form4-06172022_010602.xml 0001415889-22-006728 5810
2022-06-17 4 xslF345X03/form4-06172022_010610.xml 0001415889-22-006726 5752
2022-06-17 4 xslF345X03/form4-06172022_010627.xml 0001415889-22-006722 5798
2022-06-17 4 xslF345X03/form4-06172022_010626.xml 0001415889-22-006718 5804
2022-06-17 4 xslF345X03/form4-06172022_010613.xml 0001415889-22-006716 5762
2022-06-17 4 xslF345X03/form4-06172022_010651.xml 0001415889-22-006712 5732
2022-06-17 4 xslF345X03/form4-06172022_010652.xml 0001415889-22-006709 5754
2022-06-17 4 xslF345X03/form4-06172022_010605.xml 0001415889-22-006708 5592
2022-06-17 4 xslF345X03/form4-06172022_010604.xml 0001415889-22-006705 5598
2022-06-17 4 xslF345X03/form4-06172022_010653.xml 0001415889-22-006700 5557
2022-06-17 4 xslF345X03/form4-06172022_010659.xml 0001415889-22-006696 5579
2022-06-17 4 xslF345X03/ownership.xml 0001493152-22-017153 5684
2022-06-17 4 xslF345X03/ownership.xml 0001493152-22-017154 5684
2022-06-17 4 xslF345X03/form4-06172022_010651.xml 0001415889-22-006694 5635
2022-06-17 3 xslF345X02/ownership.xml 0001493152-22-017138 12057
2022-06-17 3 xslF345X02/ownership.xml 0001493152-22-017139 12605
2022-06-16 8-K FORM 8-K 5.07 0001104659-22-071880 000-15006 221020579 34 202895 1 1
2022-06-10 SC 13G SC 13G 0001140361-22-022594 005-37761 221009060 34 353903
2022-05-05 10-Q 10-Q 0001104659-22-056442 000-15006 22896164 34 5145924 1 1
2022-05-05 8-K FORM 8-K 2.02,9.01 0001171843-22-003323 000-15006 22896021 34 266233 1 1
2022-04-26 DEF 14A DEF 14A 0001104659-22-049942 000-15006 22851720 34 1521269
2022-02-28 10-K FORM 10K 0001104659-22-028070 000-15006 22689341 34 8423851 1 1
2022-02-28 8-K FORM 8-K 2.02,9.01 0001171843-22-001448 000-15006 22689213 34 313727 1 1
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-023142 005-37761 22634480 34 68856
2022-02-14 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-22-001595 005-37761 22625696 34 60865
2022-02-10 SC 13G CELLDEX_THERAPEUTICS_INC.txt 0000093751-22-000124 005-37761 22612847 34 8687
2022-02-10 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-22-001350 005-37761 22611430 34 102208
2022-02-09 SC 13G SCHEDULE 13G 0001104659-22-016770 005-37761 22606751 34 13179
2022-02-09 SC 13G/A filing.txt 0000315066-22-000887 005-37761 22604221 34 8657
2022-02-04 SC 13G us15117b2025_020422.txt 0000834237-22-007115 005-37761 22593338 34 13598
2022-01-28 8-K FORM 8-K 5.03,9.01 0001104659-22-008977 000-15006 22568704 34 269207 1 1
2022-01-18 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-22-000165 005-37761 22535523 34 27383
2022-01-14 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-22-000137 005-37761 22531391 34 27247
2021-12-28 4 FORM 4 - 0001179110-21-011251 12034
2021-12-10 4 FORM 4 - 0001179110-21-010820 12048
2021-12-10 4 FORM 4 - 0001179110-21-010819 9022
2021-12-10 4 FORM 4 - 0001179110-21-010818 8514
2021-11-17 4 FORM 4 - 0001179110-21-010208 14594
2021-11-16 4 FORM 4 - 0001179110-21-010165 8735
2021-11-09 10-Q 10-Q 0001104659-21-136268 000-15006 211392068 34 6231488 1 1
2021-11-09 8-K FORM 8-K 2.02,9.01 0001171843-21-007741 000-15006 211391929 34 301689 1 1
2021-11-03 4 FORM 4 - 0001179110-21-009818 17474
2021-11-03 4 FORM 4 - 0001179110-21-009816 13396
2021-11-03 4 FORM 4 - 0001179110-21-009815 8514
2021-10-12 SC 13G filing.txt 0000315066-21-001801 005-37761 211317259 34 8649
2021-08-13 4 FORM 4 - 0001179110-21-008164 7630
2021-08-13 4 FORM 4 - 0001179110-21-008163 4681
2021-08-12 4 FORM 4 - 0001179110-21-008140 14115
2021-08-09 4 FORM 4 - 0001179110-21-008010 7581
2021-08-05 10-Q 10-Q 0001104659-21-100745 000-15006 211148163 34 5817278 1 1
2021-08-05 8-K FORM 8-K 2.02,9.01 0001171843-21-005572 000-15006 211148052 34 91494
2021-07-15 424B5 424B5 0001104659-21-092200 333-249917 211091310 33 751997
2021-07-14 8-K FORM 8-K 1.01,8.01,9.01 0001104659-21-092099 000-15006 211090291 34 368023
2021-07-12 424B5 424B5 0001104659-21-091181 333-249917 211085766 33 740162
2021-07-12 8-K FORM 8-K 8.01 0001104659-21-091151 000-15006 211085559 34 30407
2021-07-01 8-K FORM 8-K 5.02,9.01 0001104659-21-088220 000-15006 211065814 34 790473
2021-06-21 4 FORM 4 - 0001179110-21-006912 5705
2021-06-21 4 FORM 4 - 0001179110-21-006911 5659
2021-06-21 4 FORM 4 - 0001179110-21-006910 5717
2021-06-21 4 FORM 4 - 0001179110-21-006909 5702
2021-06-21 4 FORM 4 - 0001179110-21-006908 5712
2021-06-21 4 FORM 4 - 0001179110-21-006907 5652
2021-06-21 4 FORM 4 - 0001179110-21-006906 5702
2021-06-21 4 FORM 4 - 0001179110-21-006905 5694
2021-06-21 4 FORM 4 - 0001179110-21-006904 5622
2021-06-21 4 FORM 4 - 0001179110-21-006903 5645
2021-06-21 4 FORM 4 - 0001179110-21-006892 5496
2021-06-21 4 FORM 4 - 0001179110-21-006890 5482
2021-06-21 4 FORM 4 - 0001179110-21-006889 5525
2021-06-21 4 FORM 4 - 0001179110-21-006888 5488
2021-06-21 4 FORM 4 - 0001179110-21-006887 5480
2021-06-17 8-K FORM 8-K 5.02,5.07,9.01 0001104659-21-082585 000-15006 211024664 34 327913
2021-06-16 S-8 FORM S-8 0001104659-21-081982 333-257137 211021441 33 79547
2021-05-06 10-Q FORM 10-Q 0001104659-21-062387 000-15006 21897700 34 4424435 1
2021-05-06 8-K FORM 8-K 2.02,9.01 0001171843-21-003256 000-15006 21897570 34 68977
2021-04-27 DEF 14A DEF 14A 0001104659-21-055589 000-15006 21858925 34 2233358
2021-03-29 10-K 10-K 0001104659-21-043161 000-15006 21781764 34 8284947 1
2021-03-29 8-K FORM 8-K 2.02,9.01 0001171843-21-002135 000-15006 21781679 34 96296
2021-02-25 SC 13G COWEN FINANCIAL PRODUCTS LLC 0001085146-21-001052 005-37761 21680022 34 27384
2021-02-16 SC 13G SC 13G 0001104659-21-023928 005-37761 21638189 34 79351
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-041686 005-37761 21628261 34 118493
2021-02-12 SC 13G/A formsc13ga.htm 0001493152-21-003530 005-37761 21623552 34 177318
2021-02-11 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-21-000324 005-37761 21620233 34 269162
2021-02-11 SC 13G/A CELLDEX THERAPEUTICS, INC. 0000902664-21-001119 005-37761 21616743 34 107745
2021-02-10 SC 13G/A cldx-13g_20201231.txt 0001037389-21-000083 005-37761 21614728 34 13562
2021-01-04 3 OWNERSHIP DOCUMENT 0001104659-21-000105 17136
2021-01-04 8-K FORM 8-K 5.02,7.01,9.01 0001104659-21-000104 000-15006 21500233 34 112442
2020-12-16 4 FORM 4 - 0001179110-20-011996 13877
2020-11-06 8-K FORM 8-K 8.01,9.01 0001104659-20-122521 000-15006 201294719 34 20794
2020-11-06 S-3ASR S-3ASR 0001104659-20-122483 333-249917 201294350 33 790358
2020-11-05 10-Q FORM 10-Q 0001104659-20-121786 000-15006 201290437 34 5272902 1
2020-11-05 8-K FORM 8-K 2.02,9.01 0001171843-20-007664 000-15006 201290300 34 91179
2020-10-22 SC 13G cldx13g.htm 0000935836-20-000571 005-37761 201252959 34 60299
2020-08-18 8-K FORM 8-K 8.01 0001104659-20-096505 000-15006 201113587 34 19024
2020-08-06 10-Q FORM 10-Q 0001104659-20-091459 000-15006 201082014 34 4879690 1
2020-08-06 8-K FORM 8-K 2.02,9.01 0001171843-20-005651 000-15006 201081439 34 90389
2020-07-24 SC 13G CELLDEX THERAPEUTICS, INC. 0000902664-20-002780 005-37761 201047008 34 108773
2020-06-26 SC 13G THE SCHEDULE 13G 0000921895-20-001867 005-37761 20995235 34 290534
2020-06-26 S-8 S-8 0001104659-20-077437 333-239463 20994059 33 53155
2020-06-19 SC 13G sc13g.htm 0001493152-20-011453 005-37761 20974581 34 173220
2020-06-19 4 FORM 4 - 0001179110-20-007598 5698
2020-06-19 4 FORM 4 - 0001179110-20-007597 5712
2020-06-19 4 FORM 4 - 0001179110-20-007596 5713
2020-06-19 4 FORM 4 - 0001179110-20-007595 5703
2020-06-19 4 FORM 4 - 0001179110-20-007594 5653
2020-06-19 4 FORM 4 - 0001179110-20-007593 5703
2020-06-19 4 FORM 4 - 0001179110-20-007592 5660
2020-06-19 4 FORM 4 - 0001179110-20-007591 5626
2020-06-19 4 FORM 4 - 0001179110-20-007590 5646
2020-06-19 4 FORM 4 - 0001179110-20-007589 5459
2020-06-19 4 FORM 4 - 0001179110-20-007588 5481
2020-06-19 4 FORM 4 - 0001179110-20-007587 5489
2020-06-19 4 FORM 4 - 0001179110-20-007586 5526
2020-06-19 4 FORM 4 - 0001179110-20-007585 5483
2020-06-18 8-K FORM 8-K 5.02,5.07,9.01 0001104659-20-074646 000-15006 20972520 34 153446
2020-06-18 SC 13G SC 13G 0001193125-20-171962 005-37761 20971348 34 115271
2020-06-17 424B5 424B5 0001047469-20-003646 333-235399 20967970 33 322108
2020-06-17 8-K FORM 8-K 1.01,8.01,9.01 0001104659-20-073843 000-15006 20967435 34 348607
2020-06-15 S-3MEF S-3MEF 0001104659-20-073505 333-239199 20964703 33 51047
2020-06-15 8-K FORM 8-K 8.01 0001104659-20-073386 000-15006 20963399 34 30069
2020-06-15 424B5 424B5 0001047469-20-003602 333-235399 20963395 33 317580
2020-06-15 424B5 424B5 0001047469-20-003601 333-235399 20963387 33 47403
2020-06-12 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-06-12 14:00:00 9999999995-20-001412 333-235399 20961810 33 1923
2020-06-12 8-K FORM 8-K 8.01,9.01 0001104659-20-072934 000-15006 20960533 34 31019
2020-06-12 424B5 424B5 0001047469-20-003564 333-235399 20960035 33 254663
2020-06-12 CORRESP filename1.htm 0001104659-20-072779 8664
2020-06-12 4 FORM 4 - 0001179110-20-007242 4663
2020-06-12 S-3/A FORM S-3/A 0001104659-20-072503 333-235399 20958224 33 221274
2020-06-11 4 FORM 4 - 0001179110-20-007218 4716
2020-06-10 4 FORM 4 - 0001179110-20-007167 4716
2020-06-10 4 FORM 4 - 0001179110-20-007166 4883
2020-06-10 4 FORM 4 - 0001179110-20-007165 4667
2020-06-10 4 FORM 4 - 0001179110-20-007164 4628
2020-06-10 4 FORM 4 - 0001179110-20-007163 4834
2020-05-06 10-Q FORM 10-Q 0001104659-20-057436 000-15006 20852811 34 4166545 1
2020-05-06 8-K FORM 8-K 2.02,9.01 0001171843-20-003372 000-15006 20852514 34 63791
2020-04-28 DEF 14A DEF 14A 0001047469-20-002644 000-15006 20825071 34 1137179
2020-03-27 424B5 424B5 0001104659-20-039253 333-214882 20748076 33 20303
2020-03-26 10-K 10-K 0001047469-20-001809 000-15006 20746239 34 8045650 1
2020-03-26 8-K FORM 8-K 2.02,9.01 0001171843-20-002037 000-15006 20746124 34 94844
2020-02-12 SC 13G cldx-13g_20191231.txt 0001037389-20-000083 005-37761 20603935 34 13529
2019-12-12 UPLOAD filename1.pdf 0000000000-19-016322 46285
2019-12-06 S-3 S-3 0001047469-19-006714 333-235399 191273114 33 246571
2019-11-12 10-Q 10-Q 0001104659-19-062181 000-15006 191206476 34 5791161 1
2019-11-12 8-K FORM 8-K 2.02,9.01 0001171843-19-007429 000-15006 191206220 34 93897
2019-08-07 10-Q 10-Q 0001104659-19-044531 000-15006 191005483 34 5432994 1
2019-08-07 8-K FORM 8-K 2.02,9.01 0001171843-19-005251 000-15006 191005356 34 98813
2019-07-09 4 FORM 4 - 0001179110-19-008540 5653
2019-07-08 3 3 0001104659-19-039565 10387
2019-06-24 8-K 8-K 5.02,7.01,9.01 0001104659-19-037195 000-15006 19915256 34 136955
2019-06-21 S-8 S-8 0001104659-19-037010 333-232255 19911592 33 87882
2019-06-21 S-8 S-8 0001104659-19-036997 333-232253 19911519 33 88872
2019-06-20 4 FORM 4 - 0001179110-19-007979 5649
2019-06-20 4 FORM 4 - 0001179110-19-007978 5699
2019-06-20 4 FORM 4 - 0001179110-19-007977 5708
2019-06-20 4 FORM 4 - 0001179110-19-007976 5699
2019-06-20 4 FORM 4 - 0001179110-19-007975 5709
2019-06-20 4 FORM 4 - 0001179110-19-007974 5691

Latest XBRL company facts

One latest value per concept from companyfacts (303 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 78.55M 2026-10-28 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
dei EntityPublicFloat Entity Public Float USD 1.30B 2025-06-30 2025 FY 10-K 2026-02-25 0001104659-26-019652
ecd CoSelectedMeasureAmt CoSelectedMeasureAmt USD 518.57M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 1.73M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.91M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 201 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 4.83M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd PeoTotalCompAmt PeoTotalCompAmt USD 5.37M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 155 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001104659-26-050884
ffd NetFeeAmt NetFeeAmt USD 0 2026-10-29 S-3ASR 2026-11-05 0001104659-26-123391
ffd TtlFeeAmt TtlFeeAmt USD 0 2026-10-29 S-3ASR 2026-11-05 0001104659-26-123391
ffd TtlOfferingAmt TtlOfferingAmt USD 0 2026-10-29 S-3ASR 2026-11-05 0001104659-26-123391
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-29 S-3ASR 2026-11-05 0001104659-26-123391
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-10-29 S-3ASR 2026-11-05 0001104659-26-123391
us-gaap AccountsAndOtherReceivablesNetCurrent Accounts and Other Receivables, Net, Current USD 355,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 11.24M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 3.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 46.61M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.48M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 23.90M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD 2.60M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -329,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 2.69B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 10.97M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 27.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 1.64M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 11.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 33,000 2013-05-02 2013 Q3 10-Q 2013-11-08 0001104659-13-082619
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 18.68M 2018-01-01 2018-03-31 2019 Q1 10-Q 2019-05-07 0001104659-19-027513
us-gaap Assets Assets USD 721.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AssetsCurrent Assets, Current USD 663.74M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 7,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 2.93M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 626.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 5,000 2021-06-30 2021 Q2 10-Q 2021-08-05 0001104659-21-100745
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 9,000 2021-06-30 2021 Q2 10-Q 2021-08-05 0001104659-21-100745
us-gaap AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) USD 211.41M 2014-06-30 2014 Q2 10-Q 2014-08-07 0001104659-14-057922
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 53.53M 2019-03-31 2019 Q1 10-Q 2019-05-07 0001104659-19-027513
us-gaap AvailableforsaleSecuritiesGrossUnrealizedGain Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) USD 86,000 2013-06-30 2013 Q2 10-Q 2013-08-06 0001104659-13-060226
us-gaap AvailableForSaleSecuritiesGrossUnrealizedLosses1 Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) USD 124,000 2013-06-30 2013 Q2 10-Q 2013-08-06 0001104659-13-060226
us-gaap BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares shares 1.22M 2016-11-29 2021 Q1 10-Q 2021-05-06 0001104659-21-062387
us-gaap BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount Business Acquisition, Goodwill, Expected Tax Deductible Amount USD 0 2016-11-29 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs USD 700,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability USD -29.62M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High USD 107.50M 2021-03-31 2021 Q1 10-Q 2021-05-06 0001104659-21-062387
us-gaap BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability USD 6.86M 2021-12-31 2022 FY 10-K 2023-02-28 0001104659-23-026701
us-gaap BusinessCombinationContingentConsiderationLiabilityMeasurementInput Business Combination, Contingent Consideration, Liability, Measurement Input Y 4 2020-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 75,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001104659-17-066472
us-gaap CashAcquiredFromAcquisition Cash Acquired from Acquisition USD 4.59M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 26.95M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -13.08M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 26.95M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -1.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 297.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 78.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 78.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap CommonStockValue Common Stock, Value, Issued USD 79,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -231.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ConstructionInProgressExpendituresIncurredButNotYetPaid Construction in Progress Expenditures Incurred but Not yet Paid USD 711,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ContractWithCustomerAssetNet Contract with Customer, Asset, after Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 1.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ConvertibleSubordinatedDebtCurrent Convertible Subordinated Debt, Current USD 12.41M 2010-12-31 2011 FY 10-K 2012-03-08 0001047469-12-002276
us-gaap CostMethodInvestmentsOriginalCost Cost Method Investments, Original Cost USD 1.80M 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap CostOfGoodsAndServicesSold Cost of Goods and Services Sold USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap CostsAndExpenses Costs and Expenses USD 247.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap DebtInstrumentInterestRateAtPeriodEnd Debt Instrument, Interest Rate at Period End (Deprecated 2014-01-31) pure 0.055 2012-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -5.20M 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001104659-17-066472
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 30.92M 2016-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 4.66M 2016-06-30 2016 Q2 10-Q 2016-08-08 0001104659-16-137913
us-gaap DeferredRentCredit Deferred Rent Credit USD 669,000 2017-09-30 2017 Q3 10-Q 2017-11-07 0001104659-17-066472
us-gaap DeferredRevenue Deferred Revenue USD 2.08M 2018-09-30 2018 Q3 10-Q 2018-11-07 0001104659-18-066648
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 13,000 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 380.40M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 245.76M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 4.49M 2018-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 392,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 37.52M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsTaxDeferredExpense Deferred Tax Assets, Tax Deferred Expense USD 86.25M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 8.86M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsTaxDeferredExpenseOther Deferred Tax Assets, Tax Deferred Expense, Other USD 1.62M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 374.50M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 1.61M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 670,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 600,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 0.04 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DefinedContributionPlanMaximumAnnualContributionPerEmployeePercent Defined Contribution Plan, Maximum Annual Contribution Per Employee, Percent (Deprecated 2013-01-31) pure 0.04 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent pure 0.6 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 2.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap Dividends Dividends USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -3.06 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.21 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -3.06 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.189 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.009 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.057 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.046 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EffectOfExchangeRateOnCashAndCashEquivalents Effect of Exchange Rate on Cash and Cash Equivalents USD -5,000 2011-01-01 2011-06-30 2011 Q2 10-Q 2011-08-04 0001104659-11-043630
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD 15,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 11.81M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 85.40M 2024-09-30 2024 Q3 10-Q 2024-11-06 0001410578-24-001766
us-gaap EquitySecuritiesFvNiCost Equity Securities, FV-NI, Cost USD 1.80M 2018-12-31 2021 FY 10-K 2022-02-28 0001104659-22-028070
us-gaap EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Equity Securities without Readily Determinable Fair Value, Amount USD 1.80M 2016-12-31 2020 Q3 10-Q 2020-11-05 0001104659-20-121786
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap FederalIncomeTaxExpenseBenefitContinuingOperations Federal Income Tax Expense (Benefit), Continuing Operations USD -48.97M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization USD 7.62M 2018-09-30 2018 Q3 10-Q 2018-11-07 0001104659-18-066648
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One USD 900,000 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Finite-Lived Intangible Asset, Expected Amortization, Year Five USD 900,000 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four USD 900,000 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three USD 900,000 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two USD 900,000 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations Foreign Income Tax Expense (Benefit), Continuing Operations USD -913,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD 50,000 2011-01-01 2011-12-31 2011 FY 10-K 2012-03-08 0001047469-12-002276
us-gaap GainLossOnSaleOfOtherAssets Gain (Loss) on Disposition of Other Assets USD 500,000 2017-01-01 2017-06-30 2017 Q2 10-Q 2017-08-08 0001104659-17-050250
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -51,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap GainLossRelatedToLitigationSettlement Gain (Loss) Related to Litigation Settlement USD -12.50M 2023-01-01 2023-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 39.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap Goodwill Goodwill USD 90.98M 2017-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 90.98M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-lived USD 3.50M 2021-07-01 2021-09-30 2021 FY 10-K 2022-02-28 0001104659-22-028070
us-gaap ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) USD 3.50M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-26 0001410578-24-000076
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 1.80M 2019-01-01 2019-03-31 2021 FY 10-K 2022-02-28 0001104659-22-028070
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -258.76M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 0 2022-01-01 2022-12-31 2023 FY 10-K 2024-02-26 0001410578-24-000076
us-gaap IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest USD -37.88M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001104659-20-121786
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxExpenseBenefitContinuingOperations Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) USD -22.20M 2012-01-01 2012-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 48.97M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 99.53M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 326,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -54.34M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount USD 19.11M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 2.18M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 14.70M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 294,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -15.38M 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncomeTaxReconciliationTaxContingenciesOther Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount USD -1.44M 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-27 0001410578-25-000216
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 11.81M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap IncreaseDecreaseInAccountsAndOtherReceivables Increase (Decrease) in Accounts and Other Receivables USD -1.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 9.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -39.38M 2010-01-01 2010-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap IncreaseDecreaseInEquitySecuritiesFvNi Increase (Decrease) in Equity Securities, FV-NI USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001104659-20-121786
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -3.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD -2.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -11,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite-lived Intangible Assets (Excluding Goodwill) USD 27.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap IntangibleAssetsGrossExcludingGoodwill Intangible Assets, Gross (Excluding Goodwill) USD 74.99M 2018-09-30 2018 Q3 10-Q 2018-11-07 0001104659-18-066648
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 27.19M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap InterestAndOtherIncome Interest and Other Income USD 19.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap InterestExpense Interest Expense USD 927,000 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 1.21M 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap InterestReceivable Interest Receivable USD 5.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap InvestmentsAndCash Investments and Cash USD 650.30M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 2.51M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.71M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 311,000 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062181
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 311,000 2019-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 742,000 2024-12-31 2024 FY 10-K 2025-02-27 0001410578-25-000216
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 804,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 524,000 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062181
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 173,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap Liabilities Liabilities USD 72.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 721.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap LiabilitiesCurrent Liabilities, Current USD 60.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap LiabilityForUncertainTaxPositionsCurrent Liability for Uncertainty in Income Taxes, Current USD 0 2016-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap LicenseCosts License Costs (Deprecated 2018-01-31) USD 700,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap LitigationSettlementExpense Litigation Settlement, Expense USD 15.00M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-08 0001104659-22-087222
us-gaap LoansPayable Loans Payable USD 472,000 2012-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 623.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap MarketableSecuritiesGainLoss Marketable Securities, Gain (Loss) USD 11,000 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -576.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NetCashProvidedByUsedInContinuingOperations Net Cash Provided by (Used in) Continuing Operations USD 94.15M 2015-01-01 2015-03-31 2015 Q1 10-Q 2015-04-29 0001104659-15-031298
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 326.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 12.90M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-09 0001104659-17-031139
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -139.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 22.40M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-09 0001104659-17-031139
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -188.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -35.26M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-09 0001104659-17-031139
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -227.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -227.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 436,000 2012-01-01 2012-09-30 2012 Q3 10-Q 2012-11-02 0001104659-12-073441
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap NumberOfStatesInWhichEntityOperates Number of States in which Entity Operates state 3 2017-09-30 2017 Q3 10-Q 2017-11-07 0001104659-17-066472
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -247.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 4.00M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 2.34M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.44M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 8.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OperatingLeasePayments Operating Lease, Payments USD 2.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 9.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 7.79M 2018-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 4.65M 2018-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 1.52M 2015-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.35M 2016-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 2.50M 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 3.14M 2018-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 167,000 2013-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 4.10M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.1 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 17.70M 2016-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 394,000 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap OtherAssetImpairmentCharges Other Asset Impairment Charges USD 1.80M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-28 0001104659-22-028070
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 9.69M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent USD 15,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-07 0001047469-18-001363
us-gaap OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax USD -30,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-05 0001104659-15-076295
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -30,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-05 0001104659-15-076295
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -3.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OtherLiabilities Other Liabilities USD 4.34M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 1.23M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 3.11M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap OtherNoncashIncomeTaxExpense Other Noncash Income Tax Expense USD -529,000 2009-01-01 2009-12-31 2011 FY 10-K 2012-03-08 0001047469-12-002276
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 1.70M 2010-01-01 2010-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap OtherSundryLiabilities Other Sundry Liabilities USD 39,000 2012-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held USD 0 2023-09-30 2023 Q3 10-Q 2023-11-02 0001410578-23-002169
us-gaap PaymentsForRestructuring Payments for Restructuring USD 470,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-07 0001104659-17-066472
us-gaap PaymentsToAcquireInProcessResearchAndDevelopment Payments to Acquire in Process Research and Development USD 3.50M 2016-01-01 2016-12-31 2020 Q3 10-Q 2020-11-05 0001104659-20-121786
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 524.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PaymentsToAcquireOtherInvestments Payments to Acquire Other Investments USD 1.80M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 6.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 3.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2022-12-31 2023 Q2 10-Q 2023-08-08 0001410578-23-001588
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 13.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap PrepaidExpenseNoncurrent Prepaid Expense, Noncurrent USD 9.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 323.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 2.96M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0001104659-23-026701
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD -11.03M 2013-01-01 2013-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 391.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 69,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-02-27 0001410578-25-000216
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 2.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -20.30M 2011-01-01 2011-06-30 2011 Q2 10-Q 2011-08-04 0001104659-11-043630
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 29.24M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 11.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 12.50M 2011-01-01 2011-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap RepaymentsOfDebt Repayments of Debt USD 2.96M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0001104659-23-026701
us-gaap RepaymentsOfOtherLongTermDebt Repayments of Other Long-term Debt USD 472,000 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap RepaymentsOfSecuredDebt Repayments of Secured Debt USD 11.03M 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap RepaymentsOfSubordinatedDebt Repayments of Subordinated Debt USD 2.96M 2009-01-01 2009-12-31 2011 FY 10-K 2012-03-08 0001047469-12-002276
us-gaap ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired USD 1.70M 2016-01-01 2016-12-31 2020 Q3 10-Q 2020-11-05 0001104659-20-121786
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 207.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 200,000 2012-12-31 2012 FY 10-K 2013-03-08 0001047469-13-002403
us-gaap RestructuringCharges Restructuring Charges USD 400,000 2018-04-01 2018-06-30 2018 Q2 10-Q 2018-08-08 0001104659-18-050496
us-gaap RestructuringReserve Restructuring Reserve USD 200,000 2018-09-30 2018 Q3 10-Q 2018-11-07 0001104659-18-066648
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -2.04B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 37,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap Revenues Revenues USD 1.76M 2018-10-01 2018-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 3.50M 2026-04-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001104659-26-091984
us-gaap RoyaltyExpense Royalty Expense USD 2.33M 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap RoyaltyRevenue Royalty Revenue (Deprecated 2018-01-31) USD 2.33M 2013-01-01 2013-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap SecuredDebt Secured Debt USD 10.10M 2013-03-31 2013 Q1 10-Q 2013-05-03 0001104659-13-036833
us-gaap SecuredDebtCurrent Secured Debt, Current USD 5.59M 2012-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap SecuredLongTermDebt Secured Long-term Debt, Noncurrent USD 5.75M 2012-12-31 2013 FY 10-K 2014-03-03 0001047469-14-001653
us-gaap SeveranceCosts1 Severance Costs USD 1.20M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-07 0001104659-18-066648
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 27.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0001104659-22-056442
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.98 2021-07-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.98 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.97 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.005 2020-07-01 2020-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.013 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.008 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 7.40M 2012-09-30 2012 Q3 10-Q 2012-11-02 0001104659-12-073441
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 46.20M 2024-09-30 2024 Q3 10-Q 2024-11-06 0001410578-24-001766
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 26.36 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-06 0001410578-24-001766
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 15.90M 2025-06-30 2025 Q2 10-Q 2025-08-07 0001410578-25-001610
us-gaap StateAndLocalIncomeTaxExpenseBenefitContinuingOperations State and Local Income Tax Expense (Benefit), Continuing Operations USD -5.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap StockGrantedDuringPeriodValueSharebasedCompensation Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture USD 250,000 2009-01-01 2009-12-31 2011 FY 10-K 2012-03-08 0001047469-12-002276
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 649.47M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 92.00M 2011-06-30 2011 Q2 10-Q 2011-08-04 0001104659-11-043630
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.067 2019-02-08 2021 FY 10-K 2022-02-28 0001104659-22-028070
us-gaap StockIssued1 Stock Issued USD 71,000 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-29 0001104659-21-043161
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 8.34M 2015-01-01 2015-12-31 2015 FY 10-K/A 2016-02-25 0001047469-16-010396
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 73.40M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001047469-19-000992
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 1.11M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 2.00M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 432.30M 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001410578-25-000216
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 323.83M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit USD 6.90M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit Tax Cuts and Jobs Act, Income Tax Expense (Benefit) USD 99.53M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-26 0001047469-20-001809
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2016-12-31 2016 FY 10-K 2017-03-14 0001047469-17-001564
us-gaap UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount Unrecorded Unconditional Purchase Obligation USD 4.50M 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD -54.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap VariableLeaseCost Variable Lease, Cost USD 900,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-25 0001104659-26-019652
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 74.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 41.58M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0001104659-21-136268
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 74.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001104659-26-123322

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →